Retatrutide

An investigational triple-incretin/glucagon agonist. Phase 2 weight-loss data were striking; it is not approved, dose and safety at scale are still being mapped, and it should not be treated as an available therapy.

Triple agonist at GIP, GLP-1, and glucagon receptors. The glucagon arm is intended to increase energy expenditure; that is also why heart-rate and hepatic signals are watched more closely than with dual agonists.

A 2023 NEJM phase 2 trial (Jastreboff et al.) reported very large mean weight reductions at higher doses over 48 weeks, with GI adverse events and a dose-related heart-rate increase. Phase 3 (TRIUMPH) is the program that will decide whether those findings hold.

Not FDA-approved. Available only in trials. Research-chemical listings online are not the investigational product.

Not a marketed medicine. Legitimate access is a clinical trial (TRIUMPH program and related studies) through a research site. There is no approved pharmacy product.

Same four pathways as the Sourcing guide.

Trials cover the investigational product. Insurance does not pay for an unapproved drug outside a protocol. Cash 'retatrutide' from a wellness clinic is not the trial product.

Research-chemical listings appeared as soon as the phase 2 paper did. Those vials are not LY3437943 from the sponsor. Identity, dose, and sterility are unknown.

Strand does not list vendors. See the grey market.

Expect the incretin GI cluster plus glucagon-related unknowns (heart rate, lean-mass, hepatic). Unapproved: no established risk-management plan for unsupervised use.

• Unapproved: no established risk-management plan for unsupervised use.
• Phase 2 showed GI effects and a dose-related heart-rate increase.
• Glucagon-arm unknowns (hepatic, lean-mass) are still being mapped in phase 3.

• Phase 2 · 2023 · N Engl J Med

  Jastreboff et al. Triple–hormone-receptor agonist retatrutide for obesity. PMID 37351564.

• TRIUMPH program

  Ongoing phase 3 weight and metabolic outcomes (ClinicalTrials.gov).